1. Home
  2. CBUS vs IOBT Comparison

CBUS vs IOBT Comparison

Compare CBUS & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cibus Inc.

CBUS

Cibus Inc.

HOLD

Current Price

$3.35

Market Cap

197.5M

Sector

Industrials

ML Signal

HOLD

Logo IO Biotech Inc.

IOBT

IO Biotech Inc.

HOLD

Current Price

$0.34

Market Cap

26.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBUS
IOBT
Founded
2010
2014
Country
United States
Denmark
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.5M
26.6M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
CBUS
IOBT
Price
$3.35
$0.34
Analyst Decision
Strong Buy
Hold
Analyst Count
2
4
Target Price
$20.00
$2.25
AVG Volume (30 Days)
539.1K
1.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
58.27
26.77
EPS
N/A
N/A
Revenue
$4,262,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$99.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
134.56
N/A
52 Week Low
$1.09
$0.21
52 Week High
$3.80
$2.79

Technical Indicators

Market Signals
Indicator
CBUS
IOBT
Relative Strength Index (RSI) 62.37 43.30
Support Level $1.34 $0.32
Resistance Level N/A $0.40
Average True Range (ATR) 0.37 0.03
MACD 0.04 0.01
Stochastic Oscillator 76.69 33.75

Price Performance

Historical Comparison
CBUS
IOBT

About CBUS Cibus Inc.

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

About IOBT IO Biotech Inc.

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Share on Social Networks: